Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9BVA0
UPID:
KTNB1_HUMAN
Alternative names:
p80 katanin
Alternative UPACC:
Q9BVA0; A6NCG6; O60620
Background:
Katanin p80 WD40 repeat-containing subunit B1, also known as p80 katanin, plays a crucial role in cellular microtubule dynamics. It is involved in severing microtubules in an ATP-dependent manner, facilitating the rapid reorganization of microtubule arrays and their transport into neuronal processes, essential for axonal growth.
Therapeutic significance:
The protein's mutation is linked to Lissencephaly 6 with microcephaly, characterized by severe brain malformations. Understanding the role of Katanin p80 could open doors to potential therapeutic strategies for this debilitating condition.